Paraganglioma: Difference between revisions
Jump to navigation
Jump to search
→Epidemiology: +HLRCC |
|||
| Line 140: | Line 140: | ||
*[[EMA]] -ve. | *[[EMA]] -ve. | ||
**+ve in [[renal cell carcinoma|RCC]]. | **+ve in [[renal cell carcinoma|RCC]]. | ||
Testing for heritable tumours: | |||
*SDHB (SDHx alterations). | |||
*FH (loss in HLRCC). | |||
*2SC (positive in HLRCC). | |||
*CAIX (+ve in VHL-related). | |||
*Alpha-inhibin (+ve in VHL-related and SHDx alterations). | |||
==EM== | ==EM== | ||